{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:03:44Z","timestamp":1790809424837,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"CSL Vifor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xkme.2026.101341","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:32:22Z","timestamp":1773855142000},"page":"101341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gabapentin Utilization and Adverse Effects Among US Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain"],"prefix":"10.1016","volume":"8","author":[{"given":"Claudio","family":"Rigatto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Schaufler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Ruessmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Pisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Cogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Karaboyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.xkme.2026.101341_bib1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2215\/CJN.05180418","article-title":"Clinical Pharmacology considerations in pain management in patients with advanced kidney failure","volume":"14","author":"Davison","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101341_bib2","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xkme.2026.101341_bib3","article-title":"Pregabalin and gabapentin for pain","volume":"369","author":"Mathieson","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.xkme.2026.101341_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s11096-022-01528-y","article-title":"The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials","volume":"45","author":"Meaadi","year":"2023","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.xkme.2026.101341_bib5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.ajkd.2021.11.007","article-title":"Higher-dose gabapentinoids and the risk of adverse events in older adults with CKD: A population-based cohort study","volume":"80","author":"Muanda","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.xkme.2026.101341_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1060028015620800","article-title":"Gabapentin: abuse, dependence, and withdrawal","volume":"50","author":"Mersfelder","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.xkme.2026.101341_bib7","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.xkme.2026.101341_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/papr.13165","article-title":"Gabapentin-Friend or foe?","volume":"23","author":"Russo","year":"2023","journal-title":"Pain Pract"},{"key":"10.1016\/j.xkme.2026.101341_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40697-016-0107-8","article-title":"Gabapentin for uremic pruritus in hemodialysis patients: A qualitative systematic review","volume":"3","author":"Lau","year":"2016","journal-title":"Can J Kidney Health Dis"},{"issue":"6","key":"10.1016\/j.xkme.2026.101341_bib11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/09546634.2016.1161161","article-title":"Gabapentin: A promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature","volume":"27","author":"Nofal","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.xkme.2026.101341_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11255-014-0795-x","article-title":"Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study","volume":"47","author":"Yue","year":"2015","journal-title":"Int Urol Nephrol"},{"issue":"3-4","key":"10.1016\/j.xkme.2026.101341_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000349943","article-title":"Uraemic pruritus: relief of itching by gabapentin and pregabalin","volume":"122","author":"Rayner","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"5","key":"10.1016\/j.xkme.2026.101341_bib14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2017.05.018","article-title":"Treatment of uremic pruritus: A systematic review","volume":"70","author":"Simonsen","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.xkme.2026.101341_bib15","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2215\/CJN.03280317","article-title":"International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis","volume":"12","author":"Rayner","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101341_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.xkme.2020.08.011","article-title":"Self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis patients","volume":"3","author":"Sukul","year":"2020","journal-title":"Kidney Med"},{"issue":"6","key":"10.1016\/j.xkme.2026.101341_bib17","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.ajkd.2023.04.008","article-title":"Pruritus in hemodialysis patients: longitudinal associations with clinical and patient-reported outcomes","volume":"82","author":"Sukul","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2026.101341_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/20543581241238808","article-title":"Pathways for diagnosing and treating CKD-associated pruritus: A narrative review","volume":"11","author":"Rigatto","year":"2024","journal-title":"Can J Kidney Health Dis"},{"issue":"7","key":"10.1016\/j.xkme.2026.101341_bib19","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1681\/ASN.2018010096","article-title":"Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients","volume":"29","author":"Ishida","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.xkme.2026.101341_bib20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/pm\/pnae027","article-title":"Patterns of gabapentin prescription and of hospitalization in a national cohort of US Veterans","volume":"25","author":"Levy","year":"2024","journal-title":"Pain Med"},{"issue":"3","key":"10.1016\/j.xkme.2026.101341_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A Phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:40:30Z","timestamp":1778143230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526001020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2590059526001020"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101341","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gabapentin Utilization and Adverse Effects Among US Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101341"}}